Aldeyra Therapeutics to Host Investor Roundtable QA
Aldeyra Therapeutics to Host Investor Roundtable QA
Event Scheduled for Thursday, June 20 at 8:00 a.m. ET
活动定于美国东部时间6月20日星期四上午8点举行
LEXINGTON, Mass.--(BUSINESS WIRE)--Jun. 12, 2024-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that the company will host an Investor Roundtable Q&A via webcast on Thursday, June 20, 2024 at 8:00 a.m. ET.
马萨诸塞州列克星敦--(美国商业资讯)--2024年6月12日--致力于发现和开发旨在治疗免疫介导和代谢疾病的创新疗法的生物技术公司Aldeyra Therapeutics, Inc.（纳斯达克股票代码：ALDX）（Aldeyra）今天宣布，该公司将于美国东部时间2024年6月20日星期四上午8点通过网络直播举办投资者圆桌问答。
The call will include prepared remarks from Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, followed by a Q&A session. The call will be open to all current and prospective Aldeyra shareholders, and participants will be able to submit questions through the webcast portal during the event. In addition, beginning Monday, June 17, investors will be able to submit questions ahead of the call via email to investorrelations@aldeyra.com.
电话会议将包括医学博士、总裁兼首席执行官托德·布雷迪准备好的讲话，随后是问答环节。电话会议将向所有现有和潜在的Aldeyra股东开放，参与者将能够在活动期间通过网络直播门户提交问题。此外，从6月17日星期一开始，投资者将能够在电话会议之前通过电子邮件将问题提交至 investorrelations@aldeyra.com。
A live audio webcast and slide presentation will be accessible from the "Investors & Media" section of the Aldeyra website at https://ir.aldeyra.com/. A replay will be available for 90 days following the event.
可从Aldeyra网站的 “投资者与媒体” 部分访问网络直播和幻灯片演示，网址为 https://ir.aldeyra.com/。活动结束后的 90 天内将提供重播。
About Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the potential treatment of immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.
关于 Aldeyra
Aldeyra Therapeutics是一家生物技术公司，致力于发现旨在治疗免疫介导和代谢性疾病的创新疗法。我们的方法是开发调节蛋白质系统的药物，而不是直接抑制或激活单一蛋白质靶标，目标是同时优化多种途径，同时最大限度地减少毒性。我们的候选产品包括 RASP（活性醛类）调节剂 ADX-629、ADX-246、ADX-248 以及用于潜在治疗免疫介导和代谢性疾病的化学相关分子。我们的后期候选产品是reproxalap，一种可能治疗干眼病和过敏性结膜炎的RASP调节剂，以及一种用于潜在治疗色素性视网膜炎的玻璃体注射甲氨蝶呤的新配方 ADX-2191。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240612329514/en/
Investor & Media:
David Burke
Tel: (917) 618-2651
investorrelations@aldeyra.com
投资者与媒体：
大卫伯克
电话：(917) 618-2651
investorrelations@aldeyra.com
Source: Aldeyra Therapeutics, Inc.
资料来源：Aldeyra Therapeutics, Inc.